Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
DiaMedica Therapeutics Inc(DMAC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DMAC
11/10/2026: DMAC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
DiaMedica Therapeutics is a clinical-stage biotechnology company focused on developing protein-based treatments for kidney diseases, notably its lead candidate, DM199. The company's primary strength lies in its proprietary rhKLK1 platform and its specialized focus on underserved renal markets. Its growth potential is entirely contingent upon successful clinical trial results and regulatory approval, which remain the key milestones for investors to monitor. However, the company faces significant risks, including the lack of revenue, high cash burn, and the inherent uncertainty of clinical development. It is best suited for speculative investors who understand the high volatility and risk profiles associated with early-stage biotech companies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure typical of clinical-stage biotech but lacks revenue growth. |
| Momentum investor | Mixed fit | Momentum may occur around clinical trial data releases, provided the signal remains positive. |
| Value investor | Weak fit | The lack of revenue and earnings makes traditional valuation metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends and must prioritize reinvestment into R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently volatile and carry high risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp price fluctuations based on trial results and regulatory updates. |
| Valuation risk | High | Without revenue, the stock price is driven by speculative potential, which can lead to significant corrections. |
| Competition risk (Biopharma) | Medium / high | Established players with deeper pockets can outspend and outcompete smaller firms in drug development. |
| Business quality | Medium | The company is in an early stage, which limits the assessment of long-term franchise durability. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | Successful clinical trials are the only path to commercialization, and failure to meet endpoints is a major risk. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 29.59% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 520.38M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 227.3K shares | Beta 0.94 | 52 Weeks Range 5.25 - 11.00 | Updated Date 11/09/2026 |
52 Weeks Range 5.25 - 11.00 | Updated Date 11/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of DM199 and the rhKLK1 platform. | The company currently makes no money; it spends cash to develop drugs hoping for future approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 461.43M | Price to Sales(TTM) 66.68 |
Enterprise Value 461.43M | Price to Sales(TTM) 66.68 | ||
Enterprise Value to Revenue 57.48 | Enterprise Value to EBITDA -0.96 | Shares Outstanding 53.93M | Shares Floating 25.30M |
Shares Outstanding 53.93M | Shares Floating 25.30M | ||
Percent Insiders 27.83 | Percent Institutions 41.02 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.